Once-weekly semaglutide 2.4 mg cut body weight by an estimated 8.3% more than placebo over 44 weeks in Chinese adults with overweight or obesity in the STEP 7 trial. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A post hoc analysis of two randomised trials found iGlarLixi produced larger 12-week HbA1c falls and faster time to target than insulin glargine in Asian adults with type 2 diabetes, though without reported between-group significance testing. PICO summary and expert commentary.
REMIND-DM is the protocol and baseline description of a cluster-randomised quality improvement trial testing PCI-report reminders to boost SGLT2 inhibitor and GLP-1RA prescribing after PCI in type 2 diabetes; no outcomes are yet reported. PICO summary and expert commentary.
A published protocol for a pragmatic cluster-randomized trial testing peer-champion interventions to increase SGLT2i and GLP-1RA prescribing in primary care, reporting design and baseline cohort only with no clinical outcomes yet. PICO summary and expert commentary.
A first-in-human Phase I dose-escalation study found the dual GLP-1/GIP receptor agonist BGM0504 was generally safe and well tolerated in 40 healthy volunteers, with dose-related weight reduction and gastrointestinal adverse events. PICO summary and expert commentary.
A 78-patient randomised placebo-controlled trial of the GLP-1 analogue Ebenatide in type 2 diabetes, with a between-group glycaemic edge at Week 24 only. PICO summary and expert commentary.
COMBINE 2 found once-weekly IcoSema superior to semaglutide 1.0 mg for HbA1c in type 2 diabetes, but body weight significantly favoured semaglutide. PICO summary and expert commentary.
A prespecified, descriptive subgroup analysis of a phase 2 survodutide trial examined how sex and baseline BMI shaped weight and waist outcomes in 387 adults with overweight or obesity. PICO summary and expert commentary.
Acute empagliflozin produced robust, comparable urinary glucose excretion in HNF1A-MODY and type 2 diabetes during a hyperglycaemic clamp. PICO summary and expert commentary.
Post-hoc STEP 6 subgroup analysis of semaglutide versus placebo in 401 Japanese and Korean adults with overweight or obesity, testing whether sex, type 2 diabetes, and other baseline factors modify weight loss. PICO summary and expert commentary.